Wakamoto Pharmaceutical Co.,Ltd.

TSE:4512.T

295 (JPY) • At close July 30, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

202420232022202120202019201820172016201520142013201220112010200920082007
Revenue 7,789.4627,738.4268,660.3778,383.1448,894.83710,917.89910,741.97510,900.87410,833.02511,194.26210,613.42510,314.2979,924.1689,429.9469,671.8159,779.70810,081.27610,181.164
Cost of Revenue 4,166.994,138.7014,552.3164,027.254,407.1684,723.9674,623.2814,816.0414,974.1684,916.4464,775.1234,710.7794,617.3934,348.3194,494.7124,096.6463,853.3113,547.063
Gross Profit 3,622.4723,540.8484,108.0614,355.8944,487.6696,193.9326,118.6946,084.8335,858.8576,277.8165,838.3025,603.5185,306.7755,081.6275,177.1035,683.0626,227.9656,634.101
Gross Profit Ratio 0.4650.4580.4740.520.5050.5670.570.5580.5410.5610.550.5430.5350.5390.5350.5810.6180.652
Reseach & Development Expenses 0513.313580.454593.958641.5141,725.5881,607.4241,378.171,141.7031,301.2240000.7920000
General & Administrative Expenses 00000006,158.325000003.4230000
Selling & Marketing Expenses 00000000000001.3210000
SG&A 4,080.2683,736.3593,326.7843,775.3234,538.9015,397.2094,833.1376,158.3254,557.084,824.7470004.7440000
Other Expenses 03,795.23515.660104.70347.131-14.705-45.38524.57749.79597.291273.243198.618283.88213.31221.217385.643270.878
Operating Expenses 4,080.2683,795.2353,966.5954,369.2815,242.6177,190.216,509.7096,158.3255,771.5176,194.595,735.5045,477.5965,285.5675,580.7555,932.4825,726.9496,024.4446,025.849
Operating Income -457.796-195.511141.467-13.386-754.947-996.278-391.015-73.49287.33983.224102.798125.9221.208-499.127-755.379-43.886203.519608.252
Operating Income Ratio -0.059-0.0250.016-0.002-0.085-0.091-0.036-0.0070.0080.0070.010.0120.002-0.053-0.078-0.0040.020.06
Total Other Income Expenses Net 465.252354.36570.107298.24451.9485.236161.216247.66182.64942.82128.871,198.724427.382371.641128.555184.884403.853109.007
Income Before Tax 7.456158.854211.574284.858-703.007-911.042-229.799174.169169.988126.045231.6681,358.773448.59-127.486-626.824140.998607.372717.259
Income Before Tax Ratio 0.0010.0210.0240.034-0.079-0.083-0.0210.0160.0160.0110.0220.1320.045-0.014-0.0650.0140.060.07
Income Tax Expense -56.98449.89573.31846.314-101.151745.497-48.51948.21275.243105.533148.324513.981265.24594.683-201.31892.479256.011310.366
Net Income 64.44108.959138.256238.543-601.856-1,656.539-181.28125.95694.74520.51283.343844.791183.344-222.17-425.50548.518351.361406.893
Net Income Ratio 0.0080.0140.0160.028-0.068-0.152-0.0170.0120.0090.0020.0080.0820.018-0.024-0.0440.0050.0350.04
EPS 1.863.143.986.87-17.34-47.73-5.223.632.730.592.424.35.27-6.38-12.31.4110.212
EPS Diluted 1.863.143.986.87-17.34-47.73-5.223.632.730.592.424.35.27-6.38-12.31.4110.212
EBITDA 438.682504.843575.806755.516-218.124-442.181243.094704.381851.647884.4721,016.5612,091.6981,264.141909.708605.723880.1441,160.7841,120.523
EBITDA Ratio 0.0560.0650.0660.09-0.025-0.0410.0230.0650.0790.0790.0960.2030.1270.0960.0630.090.1150.11